Syndax Pharmaceuticals (Nasdaq: SNDX), a US-based commercial-stage biopharmaceutical company, announced on Tuesday that it has granted inducement awards to purchase up to 124,000 shares of common stock to six new employees under the company's 2023 Inducement Plan.

The stock options are to be vested over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months subject to the employee's continued service relationship with the company through the applicable vesting dates.

Syndax's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor.